Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
67.60
-1.19 (-1.72%)
Sep 21, 2026, 4:00 PM EDT - Market closed
Cytokinetics Employees
Cytokinetics had 673 employees as of December 31, 2025. The number of employees increased by 175 or 35.14% compared to the previous year.
Employees
673
Change (1Y)
175
Growth (1Y)
35.14%
Revenue / Employee
$100,550
Profits / Employee
-$1,328,383
Market Cap
9.40B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 673 | 175 | 35.14% |
| Dec 31, 2024 | 498 | 75 | 17.73% |
| Dec 31, 2023 | 423 | 14 | 3.42% |
| Dec 31, 2022 | 409 | 156 | 61.66% |
| Dec 31, 2021 | 253 | 69 | 37.50% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Caris Life Sciences | 1,846 |
| Axsome Therapeutics | 1,346 |
| Twist Bioscience | 979 |
| Arrowhead Pharmaceuticals | 711 |
| ImmunityBio | 691 |
| Vaxcyte | 507 |
| Krystal Biotech | 295 |
| Kymera Therapeutics | 273 |
CYTK News
- 4 days ago - Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 days ago - Cytokinetics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 7 days ago - Cytokinetics Announces Call for Proposals for Ninth Annual Communications Grant Program - GlobeNewsWire
- 12 days ago - Cytokinetics Transcript: Citigroup’s Biopharma Back to School Summit 2026 - Transcripts
- 12 days ago - Cytokinetics Slides: Corporate presentation - Filings
- 19 days ago - Cytokinetics to Participate in September Investor Conferences - GlobeNewsWire
- 22 days ago - Cytokinetics announces results from ACACIA-HCM, MAPLE-HCM - TheFly
- 23 days ago - Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026 - GlobeNewsWire